SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 5 — Preventive Visit — Joe Frazier — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientJoe Frazier
Date of birth1944-01-12
IdentifiersMRN HR-BX004-SYN-TD; SSN (made up) 000-04-5590
Document date2008-07-13
AuthorClarence Whitfield, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Periodic adult preventive visit. [S]

History of Present Illness

Mr. Frazier is a 64-year-old former professional heavyweight boxer who runs a boxing gym, with type 2 diabetes, hypertension, hyperlipidemia, obesity, and compensated cirrhosis from MASLD found this spring, who comes for his yearly preventive visit eight weeks after his three-month review. He takes semaglutide 1 mg weekly, metformin, lisinopril, amlodipine 10 mg and atorvastatin without missed doses. His home blood pressure readings average 126/78. He has lost 5.4 kg since intake and has had no alcohol since the liver results. He had the dilated eye examination three weeks ago after missing the first appointment. He asked again whether the blows he took in the ring will affect his memory; today's cognitive screen was done for that reason. He has no new symptoms. [S]

ElementDetail
VisitPeriodic adult preventive visit, age 64
DiabetesA1c 7.3% at three months; semaglutide 1 mg weekly
Blood pressureHome average 126/78
LiverCompensated cirrhosis from MASLD; next surveillance ultrasound and AFP in September
Mood and memoryPHQ-2 1; MoCA 26 today

Health risk assessment. Completed by the patient with the medical assistant reading the questions aloud, because he reads with one eye, and reviewed with him by Dr. Whitfield. [S]

DomainFinding
Self-rated healthGood, and better since the spring
PsychosocialBusy and proud of his fighters; money is tight; has people he can rely on
Substance useNo alcohol since the spring; never used tobacco
Physical activityOn his feet at the gym most days; walks after dinner
NutritionSmaller portions on semaglutide; less fried food and salt
SleepSeven hours; snores at times; no witnessed pauses in breathing; not sleepy in the day
HearingNo difficulty in conversation
VisionReads with his right eye; left eye poor for years
Falls and safetyNo falls; keeps the gym floor clear; wears a seat belt
Activities of daily livingIndependent
MemoryNo trouble with appointments, money or medicines; he worries about the future

Review of Systems

SystemResultFinding
ConstitutionalNegativeNo fever; weight down by design
EyesNegativeNo new change in vision
Ears, nose, mouth, and throatNegativeNo hearing loss or gum bleeding
CardiovascularNegativeNo chest pain, palpitations or ankle swelling
RespiratoryNegativeNo cough or breathlessness
GastrointestinalNegativeNo black stools, vomiting of blood, abdominal swelling or yellowing; mild nausea in the first weeks of each semaglutide step, now gone
GenitourinaryNegativeNo trouble passing urine; gets up once at night
MusculoskeletalPositiveAching knees after long days; no joint swelling
IntegumentaryNegativeNo foot sores
NeurologicalNegativeNo headaches, tremor, numbness or unsteadiness
PsychiatricNegativeMood good; PHQ-2 1; no confusion, irritability or change in personality noticed by him or reported to him

11 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Metformin 1000 mg oral tablet, one tablet twice daily with meals; taken for yearsOne tablet twice daily with mealsOral route2008-02-16activeS
Lisinopril 20 mg oral tablet, one tablet daily; taken for yearsOne tablet dailyOral route2008-02-16activeS
Atorvastatin 40 mg oral tablet, one tablet dailyOne tablet dailyOral route2008-02-16activeS
Amlodipine 5 mg oral tablet, one tablet dailyOne tablet dailyOral route2008-03-02 to 2008-04-13completedS
Amlodipine 10 mg oral tablet, one tablet dailyOne tablet dailyOral route2008-04-13activeS
Semaglutide pen (0.25 mg or 0.5 mg per dose), 0.25 mg under the skin once weekly for four weeks, then 0.5 mg once weekly0.25 mg weekly for four weeks, then 0.5 mg weeklySubcutaneous route2008-03-02 to 2008-05-18completedS
Semaglutide pen (1 mg per dose), 1 mg under the skin once weekly1 mg once weeklySubcutaneous route2008-05-18activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2008-07-13Body height182cmS
2008-07-13Body weight98.6kgS
2008-07-13Body mass index (BMI) [Ratio]29.8kg/m2S
2008-07-13Systolic blood pressure124mm[Hg]S
2008-07-13Diastolic blood pressure76mm[Hg]S
2008-07-13Heart rate72/minS
2008-07-13Respiratory rate16/minS
2008-07-13Body temperature36.6CelS
2008-07-13Oxygen saturation in Arterial blood by Pulse oximetry98%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2008-07-13Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]1{score}S
2008-07-13Total score [MoCA]26{score}S

Physical Exam

Vital signs recorded on 2008-07-13; see the Vital Signs section. [S]

SystemFinding
ConstitutionalWell; weight 98.6 kg, BMI 29.8; blood pressure 124/76; pulse 72
EyesRight eye 20/30; left eye counting fingers at 1 meter, unchanged
EarsWhispered-voice test normal on both sides
CardiovascularRegular rhythm; no murmur; no ankle edema
RespiratoryClear to auscultation
AbdomenSoft; spleen tip not felt; no ascites; no tenderness
SkinNo jaundice, spider angiomas or foot sores
NeurologicalAlert and fluent; no tremor or asterixis; gait steady; normal finger-to-nose and rapid alternating movements
PsychiatricGood-humored and engaged

Problems

ProblemClinical statusVerificationCodeProvenance
Type 2 diabetes with hyperglycemia, about twelve years' duration, A1c 8.4% on metformin; synthetic modern episode linked to his publicly reported diabetesactiveconfirmed E11.65S — Synthetic modern diagnosis; diabetes was reported publicly during his life, but its duration and treatment here are synthetic.
Hypertension above goal on lisinopril (152/92 mmHg in the clinic); synthetic modern episode linked to his publicly reported high blood pressureactiveconfirmed I10S — Synthetic modern diagnosis; high blood pressure was reported publicly during his life.
Raised AST (48 U/L) with mildly low platelets (138) and a FIB-4 score of 3.43 at the yearly liver check, to be evaluatedresolvedconfirmed R74.01S — Synthetic presenting finding, superseded at the two-week visit by the elastography and ultrasound diagnosis.
Metabolic dysfunction-associated steatotic liver disease (MASLD): steatosis on elastography (controlled attenuation parameter 318 dB/m) and ultrasound, with diabetes, obesity, low HDL and high triglycerides, and little alcoholactiveconfirmed K76.0S — Synthetic modern diagnosis. Not part of the public record of his life; chosen to teach surveillance.
Compensated cirrhosis (compensated advanced chronic liver disease) from MASLD: liver stiffness 17.6 kPa, platelets 138, nodular liver surface and a spleen of 13.4 cm on ultrasound; no ascites, encephalopathy, bleeding or jaundice; Child-Pugh Aactiveconfirmed K74.69S — Synthetic modern diagnosis. Not part of the public record of his life; the liver cancer diagnosed three years later in the true frame does not appear in the modern episode.
Hyperlipidemia: LDL 132 mg/dL, HDL 38 and triglycerides 210, not on a statinactiveconfirmed E78.5S — Synthetic laboratory finding.
Obesity, class 1 (BMI 31.4)activeconfirmed E66.811S — Synthetic finding; described without stigma.
Reduced vision in the left eye since a cataract found at 20 (counting fingers at 1 meter); right eye 20/30activeconfirmed H54.62S — Synthetic modern measurement anchored to the documented cataract in his left eye.

Assessment and Plan

Personalized prevention plan. A written copy was given to the patient. [S]

ServiceStatusDetail
Blood pressure screeningCompleted today124/76 mmHg; home average 126/78
Colorectal cancer screeningOrderedLast colonoscopy more than ten years ago and normal; colonoscopy ordered, with anesthesia aware of his cirrhosis
Prostate cancer screeningOrderedShared decision for men 55 to 69, discussing his higher risk as a Black man; he chose a PSA test, drawn today
Lung cancer screeningNot indicatedNever smoked
Hepatitis C, hepatitis B and HIV screeningUp to dateNonreactive at intake; vaccinated against hepatitis B
Depression screeningCompleted todayPHQ-2 1
Unhealthy alcohol useUp to dateAUDIT-C 2 at intake; no alcohol since the liver diagnosis
Cognitive screeningCompleted todayMoCA 26, within the normal range; asked for by him because of his career
Diabetic eye examinationUp to dateDilated examination three weeks ago; next in one year
Diabetic foot examinationUp to dateAt intake; next in one year
Statin therapyUp to dateAtorvastatin 40 mg; LDL 68 mg/dL
Liver cancer surveillanceDueUltrasound with AFP every six months; next in September
Recombinant zoster vaccineCompleted todayDose 1 today; dose 2 in two to six months
Pneumococcal vaccineUp to datePCV20 in March
Hepatitis A and B vaccinesDueHepatitis B series complete; hepatitis A dose 2 in September
Tetanus, diphtheria, and pertussisUp to dateTdap at intake
Influenza, COVID-19 and RSV vaccinesDueAt the September visit; RSV vaccine recommended because of his age, diabetes and chronic liver disease
Aspirin for primary preventionNot indicatedBleeding risk with cirrhosis outweighs benefit

Immunizations given today: Recombinant zoster vaccine, dose 1 of 2 [S]

Guideline basis: AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma (2023); National Institute of Neurological Disorders and Stroke Consensus Diagnostic Criteria for Traumatic Encephalopathy Syndrome (2021); Adult Immunization Schedule by Medical Condition and Other Indication (2026); CMID: Clinical Monitoring Intelligence Database, diabetes type 2, hypertension and hyperlipidemia monographs (2026); Medicare Preventive Services reference: visit templates, screening cascades, and documentation elements (2026); USPSTF A and B Recommendations (2026)

Follow-up: Seven-month review in nine weeks with the surveillance ultrasound and AFP, A1c, kidney tests, the second zoster dose and the autumn vaccines. PSA result by phone. Colonoscopy to be scheduled. Next preventive visit in one year. Next scheduled visit 2008-09-14: seven-month review: six-month liver cancer surveillance ultrasound and AFP, A1c, kidney function, urine albumin and vaccines. [S]

Advance Care Planning

Voluntary advance care planning discussion of about 18 minutes, with his consent. He named a health care agent, and a health care proxy form was completed; the agent is recorded in the chart and is not named here. He said that what matters most to him is staying independent and keeping his gym open for the young fighters. He chose not to record specific treatment preferences today and would like to talk again after his next liver checks. The plan will be revisited yearly or after any serious illness. [S]